Loading...
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal su...
Saved in:
| Published in: | Hepatology |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BlackWell Publishing Ltd
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4365682/ https://ncbi.nlm.nih.gov/pubmed/25322962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|